Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial

BACKGROUND: Health-related quality of life (HRQoL) findings have varied between peanut oral immunotherapy (OIT) trials. The objective of this study was to compare changes in the HRQoL between the OIT and standard (control) treatment groups during the OPIA peanut OIT double-blind randomised controlled trial and at long-term follow-up. METHODS: OPIA was a single-centre, 3-arm, double-blind placebo-controlled trial of peanut OIT in children aged 10-16 years. Standardised questionnaires (FAQLQ, FAIM, FAQLQ-Parent Burden, PSS) and bespoke surveys were administered at 0, 6, 12 and 13.5 months, with 3-year follow-up. Changes in scores at different time points were analysed descriptively and using 2-tailed T tests. A GEE model investigated the interaction between change in HRQoL score, treatment (OIT vs. standard care) and time. 3 year follow-up surveys were analysed using descriptive statistics and qualitative analysis. RESULTS: Sixty-five subjects were randomised and 61 participants completed the study. There was no evidence of difference in HRQoL score changes between the OIT and standard treatment groups from baseline to 12 months or 13.5 months. Furthermore, achieving OPIA's primary efficacy endpoint (tolerance of ≥ 1000 mg of peanut protein (cumulative dose 1449 mg) at month 13.5 double blind placebo-controlled food challenge was not associated with a more favourable change in FAQLQ from baseline to end of study. Changes in global FAQLQ-Parent proxy (FAQLQ-PF) scores from baseline to 12 months were less favourable for carers of children who had experienced treatment-related serious adverse events compared to those without such events (mean change 0.10 vs. -0.97, 0.0063). CONCLUSIONS: OIT did not confer a HRQoL benefit over standard care in this cohort, based upon the tools used to assess HRQoL. Treatment-related serious adverse effects negatively impacted FAQLQ-Parent proxy scores.

Authors

Institutions

Publication Details

Journal
Clinical & Experimental Allergy
Published
2026-11-20
DOI
https://doi.org/10.1111/cea.70476
Primary Topic
Food Allergy and Anaphylaxis Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial

Elizabeth Helen Barnes, Peter S. Hsu, Isabelle Bosi, Dianne Elizabeth Campbell et al.
Clinical & Experimental Allergy
Food Allergy and Anaphylaxis Research
article

Quality of Life During Oral Peanut Immunotherapy in the OPIA Trial

Elizabeth Helen Barnes, Peter S. Hsu, Isabelle Bosi, Dianne Elizabeth Campbell, Alice L. Flanagan
article en

Abstract

BACKGROUND: Health-related quality of life (HRQoL) findings have varied between peanut oral immunotherapy (OIT) trials. The objective of this study was to compare changes in the HRQoL between the OIT and standard (control) treatment groups during the OPIA peanut OIT double-blind randomised controlled trial and at long-term follow-up. METHODS: OPIA was a single-centre, 3-arm, double-blind placebo-controlled trial of peanut OIT in children aged 10-16 years. Standardised questionnaires (FAQLQ, FAIM, FAQLQ-Parent Burden, PSS) and bespoke surveys were administered at 0, 6, 12 and 13.5 months, with 3-year follow-up. Changes in scores at different time points were analysed descriptively and using 2-tailed T tests. A GEE model investigated the interaction between change in HRQoL score, treatment (OIT vs. standard care) and time. 3 year follow-up surveys were analysed using descriptive statistics and qualitative analysis. RESULTS: Sixty-five subjects were randomised and 61 participants completed the study. There was no evidence of difference in HRQoL score changes between the OIT and standard treatment groups from baseline to 12 months or 13.5 months. Furthermore, achieving OPIA's primary efficacy endpoint (tolerance of ≥ 1000 mg of peanut protein (cumulative dose 1449 mg) at month 13.5 double blind placebo-controlled food challenge was not associated with a more favourable change in FAQLQ from baseline to end of study. Changes in global FAQLQ-Parent proxy (FAQLQ-PF) scores from baseline to 12 months were less favourable for carers of children who had experienced treatment-related serious adverse events compared to those without such events (mean change 0.10 vs. -0.97, 0.0063). CONCLUSIONS: OIT did not confer a HRQoL benefit over standard care in this cohort, based upon the tools used to assess HRQoL. Treatment-related serious adverse effects negatively impacted FAQLQ-Parent proxy scores.

Clinical & Experimental Allergy
The University of Sydney (AU), Royal Prince Alfred Hospital (AU), Children's Hospital at Westmead (AU), UNSW Sydney (AU), Sydney Children's Hospital (AU), National Health and Medical Research Council (AU), Neuroscience Research Australia (AU)
Food Allergy and Anaphylaxis Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon